TISIDB

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytosol Membrane Peripheral membrane protein Cytoplasmic side
Domain	PF16621 SH3 terminal domain of 2nd SH3 on Neutrophil cytosol factor 1 PF08944 NADPH oxidase subunit p47Phox PF00787 PX domain PF00018 SH3 domain
Function	NCF2, NCF1, and a membrane bound cytochrome b558 are required for activation of the latent NADPH oxidase (necessary for superoxide production).

> Gene Ontology [ TOP ]
Biological Process	GO:0002474 antigen processing and presentation of peptide antigen via MHC class I GO:0002478 antigen processing and presentation of exogenous peptide antigen GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0006612 protein targeting to membrane GO:0006801 superoxide metabolic process GO:0006968 cellular defense response GO:0019882 antigen processing and presentation GO:0019884 antigen processing and presentation of exogenous antigen GO:0042554 superoxide anion generation GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I GO:0045454 cell redox homeostasis GO:0045730 respiratory burst GO:0048002 antigen processing and presentation of peptide antigen GO:0048010 vascular endothelial growth factor receptor signaling pathway GO:0072593 reactive oxygen species metabolic process GO:0072657 protein localization to membrane GO:0090150 establishment of protein localization to membrane
Molecular Function	GO:0005543 phospholipid binding GO:0008047 enzyme activator activity GO:0009055 electron carrier activity GO:0016175 superoxide-generating NADPH oxidase activity GO:0016176 superoxide-generating NADPH oxidase activator activity GO:0016651 oxidoreductase activity, acting on NAD(P)H GO:0017124 SH3 domain binding GO:0035091 phosphatidylinositol binding GO:0043168 anion binding GO:0043325 phosphatidylinositol-3,4-bisphosphate binding GO:0050664 oxidoreductase activity, acting on NAD(P)H, oxygen as acceptor
Cellular Component	GO:0005767 secondary lysosome GO:0005791 rough endoplasmic reticulum GO:0019898 extrinsic component of membrane GO:0030139 endocytic vesicle GO:0030425 dendrite GO:0032010 phagolysosome GO:0043020 NADPH oxidase complex GO:0043025 neuronal cell body GO:0044297 cell body GO:0045335 phagocytic vesicle GO:1990204 oxidoreductase complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04062 Chemokine signaling pathway hsa04145 Phagosome hsa04380 Osteoclast differentiation hsa04666 Fc gamma R-mediated phagocytosis hsa04670 Leukocyte transendothelial migration
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-1236975: Antigen processing-Cross presentation R-HSA-2262752: Cellular responses to stress R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1236973: Cross-presentation of particulate exogenous antigens (phagosomes) R-HSA-3299685: Detoxification of Reactive Oxygen Species R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-195258: RHO GTPase Effectors R-HSA-5668599: RHO GTPases Activate NADPH Oxidases R-HSA-1222556: ROS, RNS production in phagocytes R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases R-HSA-194138: Signaling by VEGF R-HSA-4420097: VEGFA-VEGFR2 Pathway

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04062 Chemokine signaling pathway
hsa04145 Phagosome
hsa04380 Osteoclast differentiation
hsa04666 Fc gamma R-mediated phagocytosis
hsa04670 Leukocyte transendothelial migration

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-2262752: Cellular responses to stress
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1236973: Cross-presentation of particulate exogenous antigens (phagosomes)
R-HSA-3299685: Detoxification of Reactive Oxygen Species
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-195258: RHO GTPase Effectors
R-HSA-5668599: RHO GTPases Activate NADPH Oxidases
R-HSA-1222556: ROS, RNS production in phagocytes
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-194138: Signaling by VEGF
R-HSA-4420097: VEGFA-VEGFR2 Pathway

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NCF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between NCF1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
28191009	Colon Carcinoma	Inhibit immunity	Two prominent modulators of colon inflammation are represented by the closely related cytokines interleukin (IL)-12 and IL-23, which initiate adaptive Th1 and Th17 immune responses, respectively. In this study, we investigated the impact of the NADPH oxidase protein p47phox, which negatively regulates IL-12 in dendritic cells, on colon cancer development in a colitis-associated colon cancer model.

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NCF1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NCF1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.209	0.728
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.058	0.968
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.333	0.798
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.583	0.242
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.072	0.955
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.418	0.411
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.787	0.174
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.468	0.218
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.017	0.99
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.513	0.353
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.556	0.528
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.078	0.72

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NCF1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NCF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NCF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NCF1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NCF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NCF1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NCF1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NCF1
Name	neutrophil cytosolic factor 1
Aliases	p47phox; NOXO2; NCF1A; SH3PXD1A; NADPH oxidase organizer 2; chronic granulomatous disease, autosomal 1; neut ......
Chromosomal Location	7q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NCF1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting NCF1.

ID	Name	Drug Type	Targets	#Targets
DB00514	Dextromethorphan	Small Molecule	CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A ......	21

Browse NCF1